Comparison

PRDM15 Blocking Peptide (C-term)

Item no. ABC-BP1215b
Manufacturer Abcepta
Amount 500 ug
Category
Type Peptides
Format Lyophilized
Specific against other
Citations Gardiner, K., et al., Genomics 79(6):833-843 (2002).
Reymond, A., et al., Genomics 79(6):824-832 (2002).
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias PR domain zinc finger protein 15,211-,PR domain-containing protein 15,Zinc finger protein 298,PRDM15,C21orf83,ZNF298
Similar products PRDM15, C21orf83, ZNF298, PR domain zinc finger protein 15, 211-, PR domain-containing protein 15, Zinc finger protein 298
Available
Manufacturer - Category
Peptides; Blocking Peptides
Manufacturer - Targets
The synthetic peptide sequence is selected from aa 934~951 of HUMAN PRDM15
Bio Background
Similar to acetylation and phosphorylation, histone methylation at the N-terminal tail has emerged as an important role in regulating chromatin dynamics and gene activity. Histone methylation occurs on arginine and lysine residues and is catalyzed by two families of proteins, the protein arginine methyltransferase family and the SET-domain-containing methyltransferase family. Five members have been identified in the arginine methyltransferase family. About 27 are grouped into the SET-domain family, and another 17 make up the PR domain family that is related to the SET domain family. The retinoblastoma protein-interacting zinc finger geneRIZ1 is a tumor suppressor gene and a FOUNDING member of the PR domain family. RIZ1 inactivation is commonly found in many types of human cancers and occurs through loss of mRNA expression, frame shift mutation, chromosomal deletion, and missense mutation. RIZ1 is also a tumor susceptibility gene in mice. The loss of RIZ1 mRNA in human cancers was shown to associate with DNA methylation of its promoter CpG island. Methylation of the RIZ1 promoter strongly correlated with lost or decreased RIZ1 mRNA expression in breast, liver, colon, and lung cancer cell lines as well as in liver cancer tissues.
Gene Name
PRDM15
Subtitle
Synthetic peptide
Formulation
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 500 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close